JP2020504154A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020504154A5 JP2020504154A5 JP2019537269A JP2019537269A JP2020504154A5 JP 2020504154 A5 JP2020504154 A5 JP 2020504154A5 JP 2019537269 A JP2019537269 A JP 2019537269A JP 2019537269 A JP2019537269 A JP 2019537269A JP 2020504154 A5 JP2020504154 A5 JP 2020504154A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- meropenem
- cuti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010037597 Pyelonephritis acute Diseases 0.000 claims description 19
- 201000001555 acute pyelonephritis Diseases 0.000 claims description 19
- 229960002260 meropenem Drugs 0.000 claims description 15
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 10
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940109239 creatinine Drugs 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 208000019206 urinary tract infection Diseases 0.000 claims description 4
- 241000588697 Enterobacter cloacae Species 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 3
- 239000000043 antiallergic agent Substances 0.000 claims description 3
- 229940121375 antifungal agent Drugs 0.000 claims description 3
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000001802 infusion Methods 0.000 claims description 3
- 238000001990 intravenous administration Methods 0.000 claims description 3
- 229960002292 piperacillin Drugs 0.000 claims description 3
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 claims description 3
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 claims description 3
- 229960003865 tazobactam Drugs 0.000 claims description 3
- 241000194032 Enterococcus faecalis Species 0.000 claims description 2
- 241000588770 Proteus mirabilis Species 0.000 claims description 2
- 230000036760 body temperature Effects 0.000 claims description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 229940032049 enterococcus faecalis Drugs 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 210000000440 neutrophil Anatomy 0.000 claims description 2
- 244000052769 pathogen Species 0.000 claims description 2
- 230000001717 pathogenic effect Effects 0.000 claims description 2
- 230000036387 respiratory rate Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 241000588724 Escherichia coli Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 description 42
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 3
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241001025319 Etheostoma collis Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 101001035951 Homo sapiens Hyaluronan-binding protein 2 Proteins 0.000 description 1
- 102100039238 Hyaluronan-binding protein 2 Human genes 0.000 description 1
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960002770 ertapenem Drugs 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022178016A JP2023012538A (ja) | 2017-01-09 | 2022-11-07 | 細菌感染症を処置する方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762444238P | 2017-01-09 | 2017-01-09 | |
| US62/444,238 | 2017-01-09 | ||
| US201762513936P | 2017-06-01 | 2017-06-01 | |
| US62/513,936 | 2017-06-01 | ||
| PCT/US2018/012839 WO2018129479A1 (en) | 2017-01-09 | 2018-01-08 | Methods of treating bacterial infections |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178016A Division JP2023012538A (ja) | 2017-01-09 | 2022-11-07 | 細菌感染症を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020504154A JP2020504154A (ja) | 2020-02-06 |
| JP2020504154A5 true JP2020504154A5 (cg-RX-API-DMAC7.html) | 2021-02-18 |
| JP7436206B2 JP7436206B2 (ja) | 2024-02-21 |
Family
ID=62791302
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019537269A Active JP7436206B2 (ja) | 2017-01-09 | 2018-01-08 | 細菌感染症を処置する方法 |
| JP2022178016A Pending JP2023012538A (ja) | 2017-01-09 | 2022-11-07 | 細菌感染症を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022178016A Pending JP2023012538A (ja) | 2017-01-09 | 2022-11-07 | 細菌感染症を処置する方法 |
Country Status (21)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3565551T3 (pl) | 2017-01-09 | 2024-09-23 | Melinta Therapeutics, Inc. | Sposoby leczenia zakażeń bakteryjnych połączeniem waborbaktamu i meropenemu |
| CA3078238A1 (en) | 2017-10-03 | 2019-04-11 | Melinta Therapeutics, Inc. | Methods of treating bacterial infections |
| US20230230698A1 (en) * | 2020-07-27 | 2023-07-20 | Northwestern University | Antimicrobial choice algorithm for urinary tract infections |
| WO2024018372A2 (en) * | 2022-07-20 | 2024-01-25 | Sri Sathya Sai Institute Of Higher Learning | A machine learning platform for predicting uropathogens and their resistance for prescribing suitable urinary infection therapy |
| WO2024228130A1 (en) * | 2023-05-02 | 2024-11-07 | Cipla Limited | Pharmaceutical combinations and compositions thereof comprising antibacterial agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4783443A (en) | 1986-03-03 | 1988-11-08 | The University Of Chicago | Amino acyl cephalosporin derivatives |
| FR2936951B1 (fr) | 2008-10-10 | 2010-12-03 | Novexel | Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments |
| CN103180328B (zh) | 2010-08-10 | 2016-10-26 | 莱姆派克斯制药公司 | 环硼酸酯衍生物及其治疗用途 |
| US10561675B2 (en) | 2012-06-06 | 2020-02-18 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| JP2016518571A (ja) * | 2013-05-15 | 2016-06-23 | シェフラー テクノロジーズ アー・ゲー ウント コー． カー・ゲーＳｃｈａｅｆｆｌｅｒ Ｔｅｃｈｎｏｌｏｇｉｅｓ ＡＧ ＆ Ｃｏ． ＫＧ | ドラグが低減されたクラッチプレート |
| EP3285776B1 (en) | 2015-04-24 | 2022-12-21 | Melinta Therapeutics, Inc. | Dosage regimen of vaborbactam and meropenem for treating bacterial infections in subjects with reduced renal function |
| US9949995B2 (en) | 2015-09-04 | 2018-04-24 | Case Western Reserve University | Compositions and methods of treating of bacterial infections with β-lactamase inhibitors |
| PL3565551T3 (pl) | 2017-01-09 | 2024-09-23 | Melinta Therapeutics, Inc. | Sposoby leczenia zakażeń bakteryjnych połączeniem waborbaktamu i meropenemu |
-
2018
- 2018-01-08 PL PL18735813.0T patent/PL3565551T3/pl unknown
- 2018-01-08 PT PT187358130T patent/PT3565551T/pt unknown
- 2018-01-08 SG SG11201906226YA patent/SG11201906226YA/en unknown
- 2018-01-08 KR KR1020197023321A patent/KR102768209B1/ko active Active
- 2018-01-08 KR KR1020247028886A patent/KR20240133785A/ko not_active Ceased
- 2018-01-08 JP JP2019537269A patent/JP7436206B2/ja active Active
- 2018-01-08 FI FIEP18735813.0T patent/FI3565551T3/fi active
- 2018-01-08 CA CA3048650A patent/CA3048650A1/en active Pending
- 2018-01-08 NZ NZ755141A patent/NZ755141A/en unknown
- 2018-01-08 EP EP18735813.0A patent/EP3565551B1/en active Active
- 2018-01-08 AU AU2018205327A patent/AU2018205327B2/en active Active
- 2018-01-08 US US16/474,487 patent/US12478606B2/en active Active
- 2018-01-08 DK DK18735813.0T patent/DK3565551T3/da active
- 2018-01-08 ES ES18735813T patent/ES2979266T3/es active Active
- 2018-01-08 HU HUE18735813A patent/HUE066805T2/hu unknown
- 2018-01-08 WO PCT/US2018/012839 patent/WO2018129479A1/en not_active Ceased
- 2018-01-08 BR BR112019014089A patent/BR112019014089A2/pt not_active Application Discontinuation
- 2018-01-08 CN CN201880006135.5A patent/CN110402139A/zh active Pending
- 2018-01-08 MX MX2019008281A patent/MX390529B/es unknown
- 2018-01-08 EP EP23159896.2A patent/EP4212157A1/en active Pending
-
2019
- 2019-07-09 MX MX2022001704A patent/MX2022001704A/es unknown
- 2019-07-09 PH PH12019501606A patent/PH12019501606A1/en unknown
- 2019-07-09 CL CL2019001918A patent/CL2019001918A1/es unknown
- 2019-08-06 CO CONC2019/0008575A patent/CO2019008575A2/es unknown
-
2020
- 2020-07-17 CL CL2020001886A patent/CL2020001886A1/es unknown
-
2022
- 2022-11-07 JP JP2022178016A patent/JP2023012538A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feldman et al. | Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine | |
| JP2020504154A5 (cg-RX-API-DMAC7.html) | ||
| EP2473170B1 (en) | Use of aerosolized levofloxacin for treating cystic fibrosis | |
| CN115551514A (zh) | 用于治疗呼吸系统病症的药物的用途 | |
| JP2018513188A5 (cg-RX-API-DMAC7.html) | ||
| JP2020521797A5 (cg-RX-API-DMAC7.html) | ||
| Michalopoulos et al. | Cure of multidrug-resistant Acinetobacter baumannii bacteraemia with continuous intravenous infusion of colistin | |
| FI3565551T3 (fi) | Menetelmiä bakteeri-infektioiden hoitamiseksi vaborbaktaamin ja meropeneemin yhdistelmällä | |
| MX2024006271A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| US20200352986A1 (en) | Methods and compositions for alleviating respiratory dysfunction | |
| JP2012502105A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535830A5 (cg-RX-API-DMAC7.html) | ||
| US20250161250A1 (en) | Compositions and methods for treatment of idiopathic pulmonary fibrosis | |
| Kosmidis et al. | Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection | |
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| RU2500434C1 (ru) | Способ лечения сепсиса при заболеваниях органов брюшной полости и забрюшинного пространства | |
| CN103142611B (zh) | 一种组合物产品在治疗细菌感染的制药应用 | |
| JP7228895B2 (ja) | 敗血症の予防又は治療用組成物 | |
| WO2024054226A1 (en) | Gallium nitrate and dimethyl sulfoxide composition for respiratory treatment | |
| Di Venanzio et al. | Severe long term chronic complications of neuroleptic malignant syndrome: a case report | |
| CN116999538A (zh) | 一种治疗细胞因子风暴的药物及其应用 | |
| CN103040840B (zh) | 组合物的治疗应用及其产品 | |
| Sacks et al. | 1158: PLASMAPHERESIS SIGNIFICANTLY REDUCES SERUM AMLODIPINE LEVELS FOLLOWING INTENTIONAL OVERDOSE | |
| Dian et al. | Distribution and drug resistance of pathogenic bacteria in diabetic foot infection | |
| Dumbarton et al. | Prolonged methylene blue infusion in refractory septic shock: a case report Perfusion prolongée de bleu de méthylene dans un cas de choc septique réfractaire: une présentation de cas |